Tekmira Pharmaceutical Rally Fades After Ebola Diagnosis In Guniea

Tekmira Pharmaceuticals

shares are trading lower by $0.04 at $17.53 in Monday's session. The once high-flying stock in the Ebola-related sector is not reacting to news items the same way it did during its heyday last fall. Over the weekend, Guinea took emergency measures against the epidemic when six medical staff, including two doctors were diagnosed with the virus. The issue reacted in its usual manner, spiking off the headline during premarket and early into into today's session. However, after reaching $18.25 off the opening bell, it retreated well into the $17.00 handle. So far, it has found intraday support in a familiar area. After bottoming between $17.17 and $17.38 over the prior three session, it reached $17.28 before rebounding to $17.63. Over the past hour, it has been consolidating at the $17.50 level.